Carregant...
MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer
The qualification of patients with non-small cell lung cancer (NSCLC) for anti-programmed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) antibody therapy is based on an immunohistochemistry (IHC) assessment of PD-L1 expression. Immunological checkpoint inhibitors improve the overall s...
Guardat en:
| Publicat a: | Oncol Lett |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
D.A. Spandidos
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507482/ https://ncbi.nlm.nih.gov/pubmed/31186735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10207 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|